Showing 3701-3710 of 4063 results for "".
- Biogen Boosts Gene Therapy Strategy With Harvard Pact Focused on Inherited Eye Diseasehttps://modernod.com/news/biogen-boosts-gene-therapy-strategy-with-harvard-pact-focused-on-inherited-eye-disease/2477996/Mutations in more than 270 genes have been implicated in inherited eye diseases like retinitis pigmentosa. Now, Biogen has formed a research pact with Harvard’s Massachusetts Eye and Ear that’s aimed at developing a gene therapy to help some patients with these blinding diseases, according to a F
- New $1-Billion Fund Aims to Rescue “Collapsing” Antibiotic Pipelinehttps://modernod.com/news/new-1-billion-fund-aims-to-rescue-collapsing-antibiotic-pipeline/2477997/More than 20 biopharmaceutical companies on Thursday joined forces to invest nearly $1 billion in a new fund aimed at supporting the development of antibiotics to address the rapid rise of antimicrobial resistance (AMR). The AMR Action Fund, spearheaded by the International Federation of Ph
- Nicox Partner Ocumension Completes Successful Hong Kong IPOhttps://modernod.com/news/nicox-partner-ocumension-completes-successful-hong-kong-ipo/2477998/Nicox SA’s partner Ocumension Therapeutics had a successful IPO on the Hong Kong Stock Exchange and provided an update on the programs in the collaboration. Ocumension Therapeutics began trading on the Hong Kong Stock Exchange on July 10, 2020 after an IPO raising HK $1,424 (~US $184
- Accelmed Partners Completes Acquisition of TearLabhttps://modernod.com/news/accelmed-partners-completes-acquisition-of-tearlab/2477991/Private equity firm Accelmed Partners II (AP-II) completed its $25 million acquisition of dry eye device maker TearLab. As a newly formed private company, TearLab is now positioned to pursue further development of its next-generation Discovery platform and seek out targeted acquisition opp
- Oertli Instrumente Names New Director of the Boardhttps://modernod.com/news/oertli-instrumente-names-new-director-of-the-board/2477983/Andreas Bosshard, co-owner and former managing director of Oertli Instrumente AG, handed over the chairmanship of the board to Andreas Schmidheini. The reorganization became effective January 1, 2020. In 1988, Mr. Bosshard joined Oertli Instrumente AG and took over as managing director in
- Novavax Gains $1.6 Billion in Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-gains-1-6-billion-in-funding-for-covid-19-vaccine-candidate/2477984/Novavax announced that it has been awarded $1.6 billion by the US government to progress development of NVX CoV2373 and potentially deliver 100 million doses of the COVID-19 vaccine as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using Novavax’s nanop
- VisionCare Names Thomas Ruggia as New Chief Executive Officerhttps://modernod.com/news/visioncare-names-thomas-ruggia-as-new-chief-executive-officer/2477973/VisionCare announced that Thomas Ruggia has been appointed as the company’s new Chief Executive Officer, effective July 6, 2020. VisionCare provides the only FDA approved surgical treatment for macular degeneration, the telescope implant and CentraSight treatment program. “We’re thrilled
- Haag-Streit Introduces Eyestar 900 OCT Analyzerhttps://modernod.com/news/haag-streit-introduces-eyestar-900-oct-analyser/2477968/Haag-Streit has launched the Eyestar 900, a new swept-source-based precision OCT analyzer. The Eyestar 900, which recently received CE registration, is being launched in various countries and will be widely available in October 2020. The Eyestar 900’s technology enables precise measurement
- Quantel Medical Completes Acquisition of Ellexhttps://modernod.com/news/quantel-medical-completes-acquisition-of-ellex/2477963/Quantel Medical has completed its acquisition of Ellex, including the company’s laser and ultrasound technology solutions (with the exception of 2RT and iTrack), via the financial holding company Lumibird Medical.
- Oculight Launches US Subsidiary OCU L&Chttps://modernod.com/news/oculight-launches-us-subsidiary-ocu-lc/2477956/Oculight announced the launch of OCU L&C, a fully-owned U.S. subsidiary. OCU L&C will focus on the commercialization of its products in the U.S. Oculight is an ophthalmic medical device developer based in Korea founded in 2017 by Dr.